Editor's note

This ExpertREACT article was originally published on 13 October 2009. Clinical data, regulatory approvals and market positions described reflect the state of knowledge at that date.

375,000 confirmed cases: a global pandemic

WHO Update 69 reported approximately 375,000 confirmed cases and over 4,500 deaths globally from the novel H1N1 influenza A virus - though the WHO acknowledged actual case numbers were likely much higher. Many Northern hemisphere countries were already experiencing influenza-like illness (ILI) levels above baseline for the time of year. The US ACIP had published initial target group recommendations for H1N1 vaccination, identifying 159 million people in "initial target groups". Unlike seasonal flu recommendations, which skewed toward the elderly (over 65 years), H1N1 vaccination was recommended with greater emphasis on healthy younger persons (6 months to 24 years), reflecting observed disease epidemiology and hospitalisation patterns.

Commercial vaccine manufacturers had moved with surprising rapidity. GSK (Pandemrix), Sanofi Pasteur (Panenza, Humenza), Novartis (Focetria, Celtura), Medimmune (FluMist H1N1) and Baxter (Celvapan) had all either gained licensure or received positive regulatory opinions by October 2009. The diversity of technologies was remarkable - from traditional egg-based manufacturing to cell-culture (Celvapan), virosome (Inflexal), virus-like particle and adjuvanted versus non-adjuvanted formulations. H1N1 had proven considerably more immunogenic than H5N1 avian influenza had been, facilitating broadly effective single-dose schedules in many vaccine formulations.

H1N1 confirmed cases (WHO Update 69)
~375,000
Global confirmed cases with over 4,500 deaths reported; actual infection numbers estimated to be substantially higher

Technology trade-offs and safety concerns

The rapidly deployed H1N1 vaccines introduced real questions about the risk profile of relatively untested technologies. Adjuvanted formulations such as Pandemrix (containing AS03) offered antigen-sparing benefits critical for mass vaccination scale-up but raised safety surveillance priorities given limited real-world experience at population scale. The decision over which H1N1 vaccine was appropriate for each risk group - against the backdrop of seasonal vaccination also underway - was characterised by VacZine Analytics as a challenging but unavoidable task for public health authorities. The broader lesson from the H1N1 pandemic was that future vaccine technology investment should prioritise platform flexibility to enable rapid response at any time.